Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
LILRB4 STAR-T
- Development stage
- Phase 1
- Lead developer
- BriSTAR Immunotech
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
LILRB4 STAR-T is an innovative T-cell receptor-based chimeric antigen receptor (CAR) T cell therapy designed to target the immune checkpoint protein LILRB4 (Leukocyte immunoglobulin-like receptor subfamily B member 4), which is highly expressed on tumor cells and myeloid-derived suppressor cells (MDSC) in certain hematologic malignancies. The therapy involves genetically modifying a patient’s own T cells to express a synthetic TCR and antigen receptor (STAR), enabling them to recognize and kill both tumor cells expressing high levels of LILRB4 and immunosuppressive MDSC in the tumor microenvironment. This dual targeting approach aims to overcome immune suppression and improve outcomes for patients with high-risk or relapsed/refractory disease, such as multiple myeloma or acute myeloid leukemia[2][6][8].
- Other names
- LILRB4-STAR-TLILRB-4-STAR-TLILRB 4-STAR-TLILRB4 STAR-T cell therapyLILRB-4 STAR-T cell therapyLILRB 4 STAR-T cell therapyLILRB4-STAR-T-cell immunotherapyLILRB-4-STAR-T-cell immunotherapyLILRB 4-STAR-T-cell immunotherapy
02
Targets
LILRB4
Beyond the preview
Go deeper on LILRB4 STAR-T.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on LILRB4 STAR-T.